Literature DB >> 11131458

Activated protein C prevents multiple organ injury following extensive hepatectomy in cirrhotic rats.

A Yoshikawa1, T Kaido, S Seto, Y Katsuura, M Imamura.   

Abstract

BACKGROUND/AIMS: Extended hepatectomy for cirrhotic liver in patients with hepatocellular carcinoma often triggers posthepatectomy liver failure. It has been shown that the microcirculatory disturbance caused by microthrombus formation and sinusoidal endothelial cellular injury is one of the causes of post-hepatectomy liver dysfunction. We therefore investigated the effect of activated protein C (APC), a potent antithrombotic serine protease with anti-inflammatory effects, on posthepatectomy liver dysfunction and multiple organ injury in cirrhotic rats. METHODS/
RESULTS: Dimethylnitrosamine-induced cirrhotic rats underwent 70% hepatectomy and received lipopolysaccharide (200 microg/kg) 48 h later to prepare a lethal posthepatectomy acute liver failure model. APC (1500 U/kg), given intravenously 15 min before and 1 h after endotoxin challenge, attenuated liver dysfunction and decreased serum tumor necrosis factor-alpha concentration. APC significantly improved the survival rate of rats at 12 h after endotoxin challenge. Histological examination revealed that APC treatment inhibited not only intrasinusoidal fibrin deposition and massive hepatocellular necrosis but also pulmonary injury and glomerular fibrin deposition. Immunohistochemically, expression of intercellular adhesion molecule-1 on sinusoidal cells and renal glomeruli was decreased in the APC-treated animals.
CONCLUSIONS: APC administration prevented acute liver dysfunction and attenuated multiple organ injury following extended hepatectomy in cirrhotic rats, possibly via anticoagulant and anti-inflammatory effects.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11131458     DOI: 10.1016/s0168-8278(00)80128-2

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  5 in total

1.  Effect of activated protein C on pulmonary blood flow and cytokine production in experimental acute lung injury.

Authors:  Jean-Christophe Richard; Fabienne Bregeon; Véronique Leray; Didier Le Bars; Nicolas Costes; Christian Tourvieille; Franck Lavenne; Mojgan Devouassoux-Shisheboran; Gerard Gimenez; Claude Guerin
Journal:  Intensive Care Med       Date:  2007-08-02       Impact factor: 17.440

2.  Association between thrombotic risk factors and extent of fibrosis in patients with non-alcoholic fatty liver diseases.

Authors:  N Assy; I Bekirov; Y Mejritsky; L Solomon; S Szvalb; O Hussein
Journal:  World J Gastroenterol       Date:  2005-10-07       Impact factor: 5.742

3.  Drotrecogin alfa (activated) in the treatment of severe sepsis patients with multiple-organ dysfunction: data from the PROWESS trial.

Authors:  Jean-François Dhainaut; Pierre-François Laterre; Jonathan M Janes; Gordon R Bernard; Antonio Artigas; Jan Bakker; Hanno Riess; Bruce R Basson; Julien Charpentier; Barbara G Utterback; Jean-Louis Vincent
Journal:  Intensive Care Med       Date:  2003-04-24       Impact factor: 17.440

Review 4.  Emerging role of anticoagulants and fibrinolytics in the treatment of acute respiratory distress syndrome.

Authors:  Robert MacLaren; Kathleen A Stringer
Journal:  Pharmacotherapy       Date:  2007-06       Impact factor: 4.705

5.  Anticoagulant therapy in acute lung injury: a useful tool without proper operating instruction?

Authors:  Sebastian Rehberg; Perenlei Enkhbaatar; Daniel L Traber
Journal:  Crit Care       Date:  2008-09-22       Impact factor: 9.097

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.